echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Fosun Pharma's holding subsidiary ORIN1001 tablet was approved for drug clinical trial

    Fosun Pharma's holding subsidiary ORIN1001 tablet was approved for drug clinical trial

    • Last Update: 2022-05-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On February 22, Fosun Pharma announced that its holding subsidiary Fosun Hongchuang received approval from the State Drug Administration for the approval of the ORIN1001 tablet developed by it for clinical trials in the treatment of idiopathic pulmonary fibrosis
    .
    Fosun Hongchuang intends to conduct Phase I clinical trials of the new drug in China (excluding Hong Kong, Macau and Taiwan, the same below) when conditions are met
    .

    ORIN1001 tablet is a first-in-class small molecule drug with a new enzyme-type target, a new mechanism of action and a new chemical structure type independently developed by the group (ie the company and its holding subsidiaries/units, the same below).
    for the treatment of advanced solid tumors and idiopathic pulmonary fibrosis
    .
    As of the date of this announcement, the new drug is in Phase I clinical trials in the United States for the treatment of advanced solid tumors and idiopathic pulmonary fibrosis, respectively, for relapsed, refractory, and metastatic breast cancer (including triple-negative breast cancer) ) has been certified by the US FDA Fast Track Development Program (i.
    e.
    Fast Track Review); the new drug is in Phase I clinical trials in China for the treatment of advanced solid tumors
    .

    As of the date of this announcement, no drug with the same target as this new drug has been launched globally
    .

    As of January 2022, the Group has invested approximately RMB 185 million (unaudited) in the current research and development of this new drug
    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.